DailyMed Expands the Practical Use Case for a 1% Pramoxine Veterinary Rinse

DailyMed’s current label for DAVIS PRAMOXINE ANTI-ITCH describes a topical veterinary rinse built around 1% pramoxine hydrochloride, positioned for dogs, cats, puppies, and kittens with itching and flaking tied to dermatologic disease. The product is framed as a shampoo companion and leave-on or lightly rinsed conditioner, a formulation choice that matters because pruritus in companion animals is often inseparable from skin-barrier disruption. When the skin is dry, inflamed, or coated with scale, itch tends to amplify into a self-perpetuating cycle of scratching, more inflammation, and even more barrier injury.

The label does not promise disease modification. It promises temporary symptomatic relief, and in the setting of veterinary dermatology that distinction is useful. Pramoxine is a topical local anesthetic agent used to blunt itch sensation at the skin surface, while the accompanying emollient base and colloidal oatmeal are intended to soften the coat and help counter dryness and flaking. In other words, this is a formulation designed to do two jobs at once: quiet the sensory drive to scratch and improve the condition of the skin and haircoat enough to make recurrence less likely in the short term.

One sentence captures the product’s intended role: this is a comfort intervention, not a cure.

How the Formulation Is Built to Intervene at the Skin Barrier

The active ingredient is listed as pramoxine hydrochloride 1%, with the remainder of the formulation built from water, fatty alcohols, cetrimonium bromide, a modified acrylic polymer, cationic conditioning agents, trolamine, guar derivatives, oatmeal, diazolidinyl urea, and FD&C Yellow No. 5. The ingredient mix is not incidental. Fatty alcohols and conditioning polymers support spreadability and coat feel; oatmeal is commonly used in dermatologic products for its soothing and moisture-supporting properties; and the conditioning base helps the rinse remain on the coat long enough to be clinically useful.

The label directs users to apply the creme rinse after shampooing and thorough rinsing, work it well over the entire coat, avoid the eyes and nose, and leave it on for 5 to 10 minutes before lightly rinsing. For residual effect, it may also be used as a leave-on conditioner. That flexibility is clinically important in veterinary skin care because some animals need a brief topical exposure, while others benefit from a longer contact time when the goal is persistent soothing rather than a quick rinse-out.

The underlying pathophysiology is straightforward. Pruritic skin disease in animals often features a damaged stratum corneum, increased transepidermal water loss, irritation, and mechanical trauma from licking or scratching. A topical pramoxine product does not reverse the underlying allergen exposure, infection, endocrine disorder, or seborrheic process that may be driving the itch. It can, however, reduce the immediate sensory urgency that pushes an animal to traumatize already compromised skin. Breaking that loop can reduce secondary excoriation and improve comfort while the underlying condition is addressed.

Safety, Handling, and Label Status Carry the Real-World Weight

The label is blunt about several practical issues. Contact with the eyes or nose should be avoided, and if contact occurs, the area should be rinsed thoroughly. If irritation or redness persists or worsens, use should stop and a veterinarian should be consulted. The product is also labeled to be kept out of reach of children and pets, a basic but meaningful instruction for a topical veterinary preparation that may be stored alongside household grooming products.

There is also an important regulatory frame around the product. The listing identifies it as an OTC animal drug label with an unapproved drug other marketing status. DailyMed’s disclaimer states that the drug has not been found by FDA to be safe and effective, and the labeling has not been approved by FDA. For clinicians and owners, that means the label provides formulation and handling information, but not the same evidentiary assurance that accompanies an approved veterinary medicine.

The packaging details point to two commercial sizes, a 355 g bottle and a 3785 g jug, both marketed by Davis Manufacturing and Packaging Inc. The label also notes that the product is made in the USA and manufactured by Davis Manufacturing in Scottdale, Georgia. Those details may seem administrative, yet in veterinary practice they shape product selection, repeat use, and the logistics of skin-care regimens for patients that may need repeated bathing or conditioning over time.

A second practical point stands out: the instructions allow use “as often as necessary or as directed by a veterinarian.” That phrasing leaves room for the individualized care that dermatology so often demands. Some animals with seasonal flare-ups or localized irritation may need intermittent use, while others with chronic seborrheic disease or generalized pruritus may require a grooming plan built around repeated topical support, environmental control, and treatment of the underlying trigger.

The label revision date is November 12, 2026, with the current published version listed as November 16, 2026. For veterinarians and pharmacists, label currency matters because topical veterinary products often move through packaging and labeling updates without changing the clinical concept behind them. Here, the central message remains consistent: a 1% pramoxine rinse can be used to blunt itch, support skin comfort, and improve coat manageability in dogs and cats, provided the user respects the limits of a symptomatic product and watches for irritation.

The biggest clinical question is not whether pramoxine can soothe itch in the short run. It is whether the underlying dermatitis is being treated well enough that the animal does not need to keep returning to the same cycle of pruritus, trauma, and flaking.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by DailyMed Drug Label Updates.